RecruitingPhase 2NCT06144606

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Bijal D. Shah, MD
Moffitt Cancer Center
Intervention
Tecartus(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (1)

Collaborators

Kite, A Gilead Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06144606 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials